Free Trial
→ Did you grab your copy yet? (From Profits Run) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
$20.09
-2.3%		$28.27
$19.94
▼
$39.71
$409.04M1.15276,746 shs167,735 shs
Oncternal Therapeutics, Inc. stock logo
ONCT
Oncternal Therapeutics
$0.53
$0.53
$0.53
▼
$7.17
$1.56M1.1899,758 shsN/A
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
0.00%-14.62%-20.72%-25.07%-29.36%
Oncternal Therapeutics, Inc. stock logo
ONCT
Oncternal Therapeutics
0.00%0.00%0.00%0.00%0.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
$20.09
-2.3%		$28.27
$19.94
▼
$39.71
$409.04M1.15276,746 shs167,735 shs
Oncternal Therapeutics, Inc. stock logo
ONCT
Oncternal Therapeutics
$0.53
$0.53
$0.53
▼
$7.17
$1.56M1.1899,758 shsN/A
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
0.00%-14.62%-20.72%-25.07%-29.36%
Oncternal Therapeutics, Inc. stock logo
ONCT
Oncternal Therapeutics
0.00%0.00%0.00%0.00%0.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
2.83
Moderate Buy$47.50136.44% Upside
Oncternal Therapeutics, Inc. stock logo
ONCT
Oncternal Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest ONCT and ASMB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/15/2026
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (D-)
9/1/2026
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
Mizuho logo
Mizuho
Subscribe to MarketBeat All Access to unlock brokerage rankings
Set Price Target$53.00
9/1/2026
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageBuy$52.00
9/1/2026
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageBuy$52.00
9/1/2026
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
Mizuho logo
Mizuho
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetOutperform$53.00 ➝ $45.00
8/20/2026
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeHold ➝ Strong-Buy
8/18/2026
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy$50.00
(Data available from 10/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
$72.30M5.66N/AN/A$13.04 per share1.54
Oncternal Therapeutics, Inc. stock logo
ONCT
Oncternal Therapeutics
$790K1.97N/AN/A$10.19 per share0.05
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
-$6.12M$1.0219.70401.80N/A-0.06%-0.02%-0.02%11/9/2026 (Estimated)
Oncternal Therapeutics, Inc. stock logo
ONCT
Oncternal Therapeutics
-$39.48M-$11.69N/AN/AN/A-1,599.95%-177.58%-131.30%N/A

Latest ONCT and ASMB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/9/2026Q3 2026
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
-$0.6550N/AN/AN/A$9.07 millionN/A
8/13/2026Q2 2026
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
-$0.7242-$0.20+$0.5242-$0.20$8.60 million$13.37 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
N/AN/AN/AN/AN/A
Oncternal Therapeutics, Inc. stock logo
ONCT
Oncternal Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
N/A
13.99
13.99
Oncternal Therapeutics, Inc. stock logo
ONCT
Oncternal Therapeutics
N/A
2.39
2.39

Institutional Ownership

CompanyInstitutional Ownership
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
19.92%
Oncternal Therapeutics, Inc. stock logo
ONCT
Oncternal Therapeutics
16.05%

Insider Ownership

CompanyInsider Ownership
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
3.50%
Oncternal Therapeutics, Inc. stock logo
ONCT
Oncternal Therapeutics
11.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
7320.36 million19.65 millionOptionable
Oncternal Therapeutics, Inc. stock logo
ONCT
Oncternal Therapeutics
302.96 million2.63 millionNo Data

Recent News About These Companies

Oncternal Therapeutics Nears Final Liquidation Phase
February 26, 2026  |  aktiencheck.deA
Oncternal Therapeutics Enters Final Liquidation Phase
February 11, 2026  |  newscase.comN
Oncternal sells assets for up to $68m and calls it quits
July 1, 2025  |  pharmaceutical-technology.comP
ROR deal: Oncternal sells cancer assets to mystery biotech for $3M, winds down operations
July 1, 2025  |  fiercebiotech.comF
Oncternal Therapeutics Announces the Sale of Select Development Programs and the Wind-Down of its Operations
July 1, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/07/01/3108259/0/en/oncternal-therapeutics-announces-the-sale-of-select-development-programs-and-the-wind-down-of-its-operations.html
Chronic Lymphocytic Leukemia Pipeline Appears Robust With 55+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
June 17, 2025  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/GetNews/32923378/chronic-lymphocytic-leukemia-pipeline-appears-robust-with-55-key-pharma-companies-actively-working-in-the-therapeutics-segment-delveinsight/
Marginal Zone Lymphoma Pipeline Appears Robust With 50+ Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
May 21, 2025  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/GetNews/32516030/marginal-zone-lymphoma-pipeline-appears-robust-with-50-pharma-companies-actively-working-in-the-therapeutics-segment-delveinsight/
Oncternal Therapeutics Announces Intent to Voluntarily Delist from Nasdaq and Deregister with the SEC
March 7, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/03/07/3039235/0/en/oncternal-therapeutics-announces-intent-to-voluntarily-delist-from-nasdaq-and-deregister-with-the-sec.html
Oncternal Therapeutics (NASDAQ:ONCT) Stock, Short Interest Report
November 26, 2024  |  benzinga.comhttps://www.benzinga.com/quote/ONCT/short-interest
Oncternal Therapeutics Reports Q3 2024 Earnings
November 21, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/oncternal-therapeutics-reports-q3-2024-earnings-1034046484
Oncternal announces workforce reduction, executive changes
November 17, 2024  |  investing.comhttps://www.investing.com/news/sec-filings/oncternal-announces-workforce-reduction-executive-changes-93CH-3726106
Oncternal announces workforce reduction, executive changes
November 17, 2024  |  investing.comhttps://www.investing.com/news/sec-filings/oncternal-announces-workforce-reduction-executive-changes-93CH-3726106
Oncternal Therapeutics to Cut Most of Its Workforce
November 14, 2024  |  marketwatch.comhttps://www.marketwatch.com/story/oncternal-therapeutics-to-cut-most-of-its-workforce-f9445657
Oncternal Therapeutics Faces Workforce Reduction Challenges: Potential Risks and Implications
November 9, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/oncternal-therapeutics-faces-workforce-reduction-challenges-potential-risks-and-implications-1033980350
ONCT-534 Produces Tolerable Safety Outcomes in Relapsed/Refractory mCRPC
October 23, 2024  |  curetoday.comC
What’s Causing Oncternal Therapeutics Inc (ONCT) Stock’s -76.41% Drop Over the Last Six Months?
October 23, 2024  |  bovnews.comB
Oncternal Therapeutics announces updated data from Phase 1/2 study of ONCT-534
October 23, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/oncternal-therapeutics-announces-updated-data-from-phase-1-2-study-of-onct-534-1033872424
Metastatic Prostate Cancer Pipeline Insights, Treatment Drugs, Clinical Trials, and Companies 2024
October 7, 2024  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/GetNews/28927216/metastatic-prostate-cancer-pipeline-insights-treatment-drugs-clinical-trials-and-companies-2024/
Northland Securities Sticks to Its Buy Rating for Heron Therapeutics (HRTX)
September 27, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/northland-securities-sticks-to-its-buy-rating-for-heron-therapeutics-hrtx-1033801552
Earlier Info on Financial Stress; Obesity and Second Cancers; Carcinogenic Condoms?
September 19, 2024  |  medpagetoday.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Assembly Biosciences stock logo

Assembly Biosciences NASDAQ:ASMB

$20.09 -0.48 (-2.33%)
Closing price 10/16/2026 04:00 PM Eastern
Extended Trading
$20.12 +0.03 (+0.15%)
As of 10/16/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Oncternal Therapeutics stock logo

Oncternal Therapeutics NASDAQ:ONCT

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The company has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. is headquartered in San Diego, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas